Is Chronic Pain Written Into Our Genes?
A landmark 2026 genetic study involving more than 1.2 million people reveals hundreds of pain-associated genomic regions—and new clues connecting chronic pain, inflammation, brain biology, and substance use disorders
Biotech International Institute (BII)
The Next Generation of Precision Neuroscience: Five Discoveries Redefining Brain Research
Tuesday, November 17, 2026
Introduction: Why Do Some People Develop Chronic Pain While Others Recover?
Imagine two people experiencing similar injuries.
Both receive medical attention.
Both experience pain during the initial healing process.
Over time, one person's discomfort gradually improves.
The other continues experiencing pain long after the expected period of recovery.
Why?
Is the difference related to the original injury?
The nervous system's response?
Inflammation?
Stress-related biology?
Or could inherited genetic differences influence how susceptible someone is to persistent pain?
For decades, scientists have recognized that chronic pain is not a single biological condition.
It can involve peripheral nerves, the spinal cord, brain networks, immune signaling, and changes in sensory processing.
It also interacts with sleep, psychological health, previous experiences, and environmental conditions.
But understanding why some individuals develop persistent pain remains one of neuroscience's greatest challenges.
Now, a major study published November 12, 2026, in Nature Neuroscience provides an unprecedented view of pain's genetic complexity.
Researchers analyzed information from more than 1.2 million individuals across three major biobanks.
They identified 343 independent genomic regions associated with multidimensional pain, including 92 new pain associations.
They also identified hundreds of genes that may help researchers understand the molecular pathways contributing to pain susceptibility.
Perhaps most intriguingly, the results revealed overlapping genetic relationships between pain and psychiatric disorders, substance use disorders, inflammatory measures, and aspects of brain structure.
These findings raise an important possibility.
Chronic pain may involve many overlapping biological vulnerabilities rather than one universal molecular mechanism.
For Biotech International Institute, this discovery reinforces why more precise neurological research must begin with a deeper understanding of the mechanisms underlying different pain conditions.
---
1. What Is Chronic Pain?
Pain is a protective biological experience.
It can alert a person to injury, inflammation, or potentially harmful conditions.
However, chronic pain is not simply a normal warning signal that continues for an unusually long time.
Chronic pain generally refers to pain that persists or recurs for longer than three months.
It can occur with an identifiable underlying disease or injury.
In other cases, persistent pain may become a major health condition in its own right.
Researchers distinguish several important processes.
Nociceptive pain is associated with actual or threatened damage to non-neural tissue and activation of nociceptors.
Neuropathic pain results from a lesion or disease of the somatosensory nervous system.
Nociplastic pain involves altered nociception without clear evidence that ongoing tissue damage or a somatosensory lesion fully explains the experience.
These mechanisms can coexist.
A person may experience more than one pain mechanism at the same time.
This complexity presents a challenge for drug development.
A molecular pathway important in one pain condition may be less relevant in another.
2. Can Genetics Influence Pain Susceptibility?
Human genetics can influence many aspects of nervous system function.
Genes contribute to the development and operation of sensory receptors, ion channels, signaling proteins, inflammatory pathways, and cellular maintenance systems.
Some rare genetic conditions demonstrate especially strong relationships between specific genes and pain perception.
For example, particular variants affecting the SCN9A gene, which encodes the sodium channel Naᵥ1.7, can cause profound changes in pain sensitivity.
But most chronic pain is not explained by one rare gene variant.
Instead, common pain conditions appear to have polygenic components.
Polygenic means that many genetic variants, often with individually small effects, contribute to variation in a trait.
Those effects interact with environmental and biological influences.
This is why a large genetic study can identify important associations without being able to predict with certainty whether any particular person will develop chronic pain.
Genes may influence vulnerability.
They do not determine every outcome.
3. The November 2026 Discovery: More Than 1.2 Million Individuals
The study was titled:
Gene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of more than 1.2 million individuals.
The research was led by Sylvanus Toikumo, Christal Davis, Zeal Jinwala, Yousef Khan, and colleagues, including senior researcher Henry R. Kranzler.
The investigators combined genetic data from three major research resources:
- The Million Veteran Program
- UK Biobank
- FinnGen
Together, the datasets included 1,235,695 individuals of European ancestry.
This scale is important because the genetic influences on common conditions are often small.
A study involving a few hundred people may not have adequate statistical power to detect them reliably.
Much larger samples can reveal associations that smaller investigations overlook.
But size alone does not guarantee clinical usefulness.
Researchers must also determine whether the findings are reproducible, biologically meaningful, and applicable across different populations.
4. Why Did Researchers Study Multidimensional Pain?
One of the most interesting features of the research was how pain was measured.
The three biobanks did not use identical definitions.
The Million Veteran Program provided information about pain intensity over time.
UK Biobank included measures concerning the number of painful body sites.
FinnGen contributed diagnosis-based pain information.
Rather than treating these differences as entirely incompatible, the researchers constructed a multidimensional pain framework.
This approach considered complementary aspects of pain severity, anatomical distribution, and clinical diagnosis.
Why is that important?
Because pain is not one easily measured biological characteristic.
Two individuals may report similar pain intensity but experience pain in different body regions.
Another person may have widespread pain with a different underlying diagnosis.
Combining related measurements can reveal shared genetic contributions.
However, it also introduces limitations.
A multidimensional genetic association may not apply equally to every specific pain condition.
Future studies must investigate more precisely defined pain subtypes.
5. The Major Finding: 343 Genomic Regions Associated With Pain
The researchers performed a genome-wide association study, commonly called a GWAS.
A GWAS examines genetic variants across the genome to identify statistical relationships with a particular trait.
In this case, the investigators compared genetic information with measures of multidimensional pain.
They identified 343 independent associated genomic regions, including 92 new pain associations.
These findings greatly expand the catalog of genetic regions potentially relevant to persistent pain.
But an important distinction is necessary.
A statistically associated genomic region is not automatically a proven pain-causing gene.
Some regions contain several genes.
Certain variants influence gene regulation rather than directly altering a protein.
Others may be correlated with the actual functional variant because neighboring genetic variants are inherited together.
Therefore, discovering an association is usually the beginning of a biological investigation.
It identifies a location worth studying.
It does not necessarily identify the causal molecular mechanism.
6. Why 490 Prioritized Genes Matter
The researchers went beyond identifying genomic regions.
They used multiple layers of molecular data to prioritize 490 genes potentially associated with multidimensional pain.
This approach is often called multi-omic integration.
Different omic technologies measure different biological features.
Genomics investigates DNA variation.
Transcriptomics investigates RNA expression.
Proteomics investigates proteins.
Epigenomics investigates regulatory features influencing gene activity.
By combining these data types, researchers can generate hypotheses about which genes may connect genetic variation to biological function.
Some prioritized mechanisms involved neuronal processes.
Others related to immune or metabolic regulation.
The study highlighted candidate biological themes involving axonal transport, synaptic vesicle recycling, inflammatory biology, and cellular structural stability.
These are scientifically valuable leads.
However, the 490 genes were prioritized computationally and statistically.
They have not all been established experimentally as causal drivers of chronic pain.
7. Why the Brain Matters in a Genetic Study of Pain
Pain often begins with signals from peripheral tissues.
But persistent pain involves more than the initial sensory input.
Signals are processed through the spinal cord and distributed brain networks.
These networks contribute to sensory discrimination, attention, emotional experience, memory, and behavior.
The new study found that some genetic variants associated with multidimensional pain were also associated with brain imaging-derived characteristics.
These included relationships involving cortical surface area and thickness.
This suggests that genetic influences on pain may overlap with biological factors affecting aspects of brain organization.
But the findings do not demonstrate that a particular brain shape causes pain.
Brain structure and pain susceptibility may reflect interacting developmental and genetic processes.
And an association in a population does not necessarily describe a meaningful anatomical abnormality in an individual.
The key insight is that pain-related genetics extends beyond peripheral sensory receptors.
8. The Unexpected Connection Between Pain and Mental Health
Chronic pain commonly occurs alongside depression, anxiety-related symptoms, and other psychiatric conditions.
These relationships are often discussed clinically.
But the new study investigated whether some of the associations also reflect shared genetic influences.
The researchers compared multidimensional pain with 80 other complex traits.
After correcting for multiple comparisons, they identified genetic correlations with 59 traits.
These included several psychiatric conditions and psychological characteristics.
The researchers also used statistical approaches to investigate possible directional relationships.
For certain depression-related and post-traumatic stress-related traits, analyses supported potentially bidirectional relationships.
This raises the possibility that biological vulnerabilities associated with pain and psychiatric symptoms influence one another.
However, genetic correlation is not evidence that either experience is imaginary or purely psychological.
Pain is a genuine sensory and emotional experience.
Psychiatric conditions are also complex biological and clinical conditions.
The observed overlap does not eliminate the importance of tissue injury, neurological disease, or other physical mechanisms.
9. Why Pain and Substance Use Disorders Shared Genetic Signals
One of the most important aspects of the study concerns substance use disorders.
The researchers found genetic overlap between multidimensional pain and several substance use-related traits.
Their analyses also suggested possible causal relationships between genetic liability for pain and certain substance use disorder outcomes.
This is particularly relevant to research involving long-term pain management and addiction vulnerability.
But careful interpretation is essential.
The study does not establish that chronic pain inevitably leads to addiction.
Nor does it demonstrate that everyone with chronic pain has an increased individual risk of developing a substance use disorder.
Genetic susceptibility represents only one component of risk.
Medication exposure, clinical care, psychiatric conditions, environment, trauma, social factors, and individual circumstances also matter.
The results provide an opportunity to investigate shared biological pathways.
For example, researchers might ask whether some molecular mechanisms influence both pain-related processing and reward-related learning.
That is a research hypothesis—not proof that these conditions share a single cause.
10. What Is Pleiotropy?
The article's title includes an important scientific term: pleiotropy.
Pleiotropy occurs when a genetic variant influences more than one trait.
For example, a genetic region may be associated with pain and with another neurological or metabolic characteristic.
This can happen through several mechanisms.
A gene might influence a cellular process relevant to both traits.
Or a regulatory variant might affect different tissues in different ways.
In some cases, genetic associations may also reflect complex statistical relationships rather than one straightforward causal pathway.
Pleiotropy is important because diseases rarely exist in isolation.
The same biological networks may participate in multiple functions.
But discovering shared genetic influences does not automatically mean that treating one condition will treat another.
A proposed therapeutic relationship must be demonstrated experimentally.
11. Inflammation: Another Layer of Pain Biology
The study also investigated relationships between pain-associated genetic factors and inflammatory measurements.
One notable finding involved C-reactive protein, or CRP.
CRP is a circulating protein commonly measured as a marker of systemic inflammation.
Researchers found genetic relationships between multidimensional pain and CRP levels.
They also reported findings from genetic causal-inference analyses involving these traits.
This supports further investigation of inflammatory biology in chronic pain.
However, CRP is not specific to one disease.
Its levels can change under many different physiological and pathological conditions.
An elevated CRP measurement does not establish the cause of someone's pain.
Likewise, a genetic association with CRP does not prove that reducing CRP itself would relieve chronic pain.
For future research, investigators need to determine which inflammatory pathways contribute directly to specific pain conditions.
12. What Did the Study Reveal About Sex Differences?
Chronic pain affects women and men differently in many epidemiological and clinical contexts.
The researchers therefore conducted separate genetic analyses by sex.
They identified 115 independent associated regions in the male analysis and 12 in the female analysis.
At first glance, this might suggest profound differences in genetic architecture.
But the investigators cautioned against that interpretation.
The male and female datasets differed substantially in sample size and cohort composition.
The male analysis included 583,066 participants, whereas the female analysis included 241,266.
Additional comparisons suggested that many apparent differences reflected statistical power and characteristics of the biobanks rather than clearly established biological differences between sexes.
This is a crucial scientific lesson.
A difference in the number of discovered genetic associations does not necessarily mean one sex has more biological causes of pain.
Larger, more balanced, and more diverse studies are needed.
This also complements BII's earlier discussion of sex-related neuroimmune mechanisms in pain.
Population-genetic associations and cellular immune experiments provide different forms of evidence and should not be conflated.
13. Why Ancestry Diversity Is a Major Limitation
The study was unusually large.
However, the primary analysis focused on individuals of European ancestry.
That limits the extent to which the results can be generalized.
Genetic variant frequencies and relationships among neighboring variants can differ across populations.
Environmental exposures, health systems, and social conditions also influence pain.
A genetic prediction model developed mainly using one ancestry group may perform less accurately in others.
This is one of the major challenges facing precision medicine.
Greater dataset size is valuable.
But population diversity is equally important.
Future pain-genomics research should include broader ancestral representation and careful validation across different populations.
14. Does This Mean Scientists Can Predict Chronic Pain From DNA?
Not reliably enough for routine individualized clinical use based on this study.
Researchers can combine many genetic variants into a polygenic score.
Such scores may help investigate statistical differences in genetic susceptibility across populations.
But they do not establish whether an individual currently has pain.
They cannot identify every cause of a person's symptoms.
And they cannot accurately predict all future pain outcomes.
A useful clinical prediction tool would need to demonstrate reliable performance across relevant populations and settings.
It would also need to add information beyond established clinical measurements.
The 2026 study expands our understanding of genetic associations.
It does not provide a validated diagnostic or prognostic genetic test for chronic pain.
15. Could Genetic Discoveries Eventually Support More Precise Pain Research?
Potentially.
One of the central goals of human genetics is to identify biological mechanisms that contribute to disease.
If a genetic association points toward a particular cellular pathway, researchers may investigate whether that pathway is functionally important.
They can then examine its role in suitable human-derived systems or experimental models.
This could help distinguish pain subtypes involving different mechanisms.
For example, one condition may involve peripheral neuronal hyperexcitability.
Another may involve immune-related processes.
Another may involve altered central nervous system processing.
But the next step after genetic discovery is not immediately developing a treatment.
Researchers need to establish which genes and molecular pathways are causal.
They must also determine whether modifying those pathways produces meaningful effects without unacceptable risks.
Precision research requires mechanism validation, not just statistical association.
16. What This Means for NeuroRelief-P™
At Biotech International Institute, NeuroRelief-P™ is a research-stage precision-peptide program exploring hypotheses involving chronic and neuropathic pain modulation.
The November 2026 genetics study is scientifically relevant because it reinforces the heterogeneity of pain biology.
Different patients may experience pain through different combinations of peripheral, central, inflammatory, and other mechanisms.
For future research planning, these findings highlight the importance of defining the intended target population and selecting appropriate biological endpoints.
Potential questions include:
- Which pain mechanism is being investigated?
- Which molecular pathway is hypothesized to be relevant?
- Is the target expressed in an appropriate cellular population?
- Can the candidate demonstrate target engagement?
- Are functional effects reproducible?
- Does the research model reflect the intended pain condition?
- Can changes in biomarkers be connected to meaningful outcomes?
However, the new genetic study did not investigate NeuroRelief-P™.
BII has not established that NeuroRelief-P™ interacts with any of the newly identified genomic regions or prioritized genes.
No analgesic efficacy, clinical benefit, or individualized genetic-response relationship has been demonstrated for this program.
Its connection to the study is methodological and research-oriented.
17. Why the Pain–Addiction Relationship Matters for NeuroReset™
BII's NeuroReset™ platform explores research-stage hypotheses involving post-dependency neural adaptation, reward-related biology, and recovery-associated mechanisms.
The new study's findings involving shared pain and substance use-related genetic factors are therefore relevant to our broader scientific interests.
They suggest that some biological vulnerabilities associated with pain may overlap with those associated with substance use disorders.
But this does not mean that treating pain will automatically reverse addiction-related neural adaptations.
Nor does it demonstrate that a compound affecting reward-related biology will necessarily reduce pain.
These are separate scientific questions.
The study did not test NeuroReset™.
It provides no evidence that NeuroReset™ prevents substance use disorders, reduces relapse risk, or treats chronic pain.
For future research, the findings could inform questions about shared biological pathways, provided those connections are independently justified and tested.
18. How Should Biotechnology Interpret Large Genetic Studies?
Large genetic datasets can be extremely valuable.
But scientific credibility depends on interpreting them at the correct level.
A genome-wide association can identify statistical relationships.
Multi-omic analysis can prioritize candidate genes.
Functional experiments can test whether those genes influence relevant biological processes.
Pharmacological studies can determine whether an investigational compound modifies the proposed mechanism.
Independent replication can test the reliability of the finding.
And clinical research is required to establish meaningful patient benefits and safety.
These are distinct levels of evidence.
A genetic association is not a validated molecular target. A validated target is not an effective treatment. And a promising preclinical result is not clinical proof.
This distinction is particularly important for research-stage biotechnology organizations.
19. What Scientists Still Need to Discover
The new study raises several important questions.
Which of the 343 associated genomic regions contain functionally important variants?
Which of the 490 prioritized genes contribute causally to specific pain conditions?
Do some genetic pathways influence both chronic pain and substance use vulnerability?
How do pain-associated variants affect sensory-neuron excitability?
Which findings operate primarily through brain circuits, immune cells, or peripheral tissues?
Can researchers identify pain subtypes with more specific genetic profiles?
Which associations remain robust across different ancestral populations?
How do biological sex, environmental conditions, and clinical history interact with genetic susceptibility?
Can patient-derived cellular models help validate candidate mechanisms?
And can any of these discoveries eventually produce safer, more effective, non-opioid approaches to pain management?
These questions will determine the broader translational importance of the findings.
Closing Thought: Chronic Pain Is Not Simply Written Into Our DNA
The November 2026 discovery provides a much more detailed picture of chronic pain genetics.
More than 1.2 million individuals contributed to the analysis.
Hundreds of genomic regions were associated with multidimensional pain.
Hundreds of genes were prioritized for further investigation.
And researchers identified genetic overlap involving psychiatric conditions, substance use disorders, inflammation, and brain-related characteristics.
The findings show that inherited variation matters.
But they also reinforce something equally important.
Chronic pain cannot be explained by genetics alone.
Pain emerges through interactions among biological susceptibility, nervous system function, tissue conditions, previous experiences, and environmental influences.
Two individuals may have similar symptoms but different contributing mechanisms.
And two individuals with similar genetic vulnerabilities may experience very different outcomes.
For Biotech International Institute, this is the scientific opportunity.
The future of pain research may depend on moving beyond broad labels toward a more precise understanding of the mechanisms relevant to each condition.
Not every genetic association will become a therapeutic target.
Not every molecular target will lead to an effective treatment.
But carefully validated discoveries can help scientists ask better questions and design more informative experiments.
Perhaps the most important lesson is not that chronic pain is written into our genes, but that our genes provide one part of a much larger biological story.
Understanding the rest of that story will require collaboration across genetics, neuroscience, immunology, pharmacology, and clinical medicine.
Mechanism First. Validation Always.
Biotech International Institute
Research-stage. Built for validation.
Science. People. Communities. A Healthier Tomorrow.
---
Scientific References
1. Toikumo, S., Davis, C., Jinwala, Z., Khan, Y., Jennings, M., et al. (2026).
Gene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of more than 1.2 million individuals.
Nature Neuroscience. Published November 12, 2026.
2. National Library of Medicine — PubMed (2026).
Gene discovery and pleiotropic architecture of multidimensional pain in a genome-wide association study of more than 1.2 million individuals.
PMID: 43020908.
Research disclosure: This article discusses independent population-genetic research. The findings identify statistical genetic associations and prioritized candidate genes; they do not establish genetic determinism, an individualized diagnostic test, or clinically validated treatments. NeuroRelief-P™ and NeuroReset™ remain investigational BII research programs. No activity involving the genes identified in this study or clinical therapeutic effects has been demonstrated for these candidates.